ClinicalTrials.gg
Active, not recruitingNCT03991923Updated Apr 21, 2026

Non-ischemic Preservation of the Donor Heart in Heart Transplantation

An interventional study of XVIVO heart preservation devices and Standard ICSS in Heart Transplantation, sponsored by XVIVO Perfusion. Active, not recruiting at 15 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by XVIVO Perfusion · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts intended to be transplanted, to non-ischemic heart preservation (NIHP) in a randomized clinical multicentre trial. The primary hypothesis is that the non-ischemic hypothermic cardioplegic preservation (NIHP) is safe and superior to ischemic cold static storage (ICSS) of donor hearts. The study will investigate the safety and superiority of the new methodology in terms of improved immediate and prolonged organ function in adult heart transplanted patients.

Read the detailed description

This study will investigate if non-ischemic heart preservation (NIHP) with the XVIVO heart preservation devices could improve clinical outcome of patients receiving hearts after use of the technology compared to after use of standard cold ischemic preservation. This will be investigated in a European multicentre randomized controlled clinical trial. For technical reasons, blinding to the involved clinical personnel is not possible, however, biopsies will be blinded to study pathologists. The trial will include 202 recipients that have been randomized through their heart donor. The primary outcome of the study is a clinically relevant composite including graft survival, primary graft dysfunction, rejection and use of circulatory mechanical support, within 30 days and also including Cardiac Allograft Vasculopathy within 12 months. As secondary outcomes, molecular markers related to cardiac injury CKMB, ProBNP and TNI will be investigated as well as markers of the inflammatory response. Safety aspects such as effect on other organs and machine defects will also be monitored. The study population is adults, listed for heart transplantation and donors accepted as heart donors according to standard hospital procedures. Specific recipient exclusion criteria related to pre-transplant ECMO support, patients undergoing pre-transplant desensitization protocol, patients with Grown-Up Congenital Heart Disease, patients with severe kidney or liver dysfunction, patients with septicaemia, and patients diagnosed with Systemic Lupus Erythematous, sarcoidosis or amyloidosis are excluded. Cardiac death donors and donors with previous sternotomy are excluded. The study hypothesis is that NIHP better preserves the endothelium and myocyte function of the heart resulting in improved short- and medium-term recipient outcome, without inducing any new significant risks to the retrieved heart or the recipient. This is believed to be accomplished through continuous oxygenation of the heart via perfusion of the coronary arteries using an optimized preservation solution, mimicking the normal environment for the endothelium.

02

Conditions studied

  • Heart Transplantation

Keywords

  • Non Ischemic Heart Preservation (NIHP)
  • Ischemic cold static storage of donor hearts (ICSS)
03

In context

Lead sponsor

XVIVO Perfusion is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria recipient:

  • Age ≥18 years
  • Signed form
  • Listed for heart transplantation

Inclusion criteria donor:

  • Age ≥18 and ≤70 years
  • Accepted as heart donor by the transplant team
  • (Research consent from the donor if required in country)

Exclusion Criteria recipient:

  • Previous solid organ transplantation
  • Grown-up congenital heart disease (GUCH)
  • Kidney failure \<40 at listing, calculated by CDK-EPI Creatinine, or ultrafiltration or dialysis or rapidly deteriorating kidney function due to a diagnosed renal disease
  • Coagulopathy due to known hepatic disease or heparin induced thrombocytopenia
  • Subject diagnosed with Systemic Lupus Erythematous, sarcoidosis or amyloidosis
  • Known ongoing septicemia defined as positive blood culture immediately prior to the transplant (including with a durable VAD)
  • Incompatible blood group
  • Not able to understand the information provided during the informed consent procedure
  • Combined organ transplantation candidates
  • Subject already enrolled in another transplant related intervention study
  • Subjects under pre-transplant desensitization protocol (including plasma exchange in conjunction with the transplant surgery)
  • Mechanical circulatory support pre-transplantation (except durable Left ventricular assist device or Intra-aortic balloon pump)

Exclusion criteria donor:

  • Previous sternotomy
  • DCD hearts
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Non-ischemic heart preservation (NIHP)

    Continous cold cardioplegic perfusion of hearts

    Device: XVIVO heart preservation devices

  • Active comparator
    Ischemic cold static storage (ICSS)

    Standard preservation technique

    Device: Standard ICSS

Interventions

  • DeviceXVIVO heart preservation devices

    The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.

  • DeviceStandard ICSS

    Cold static preservation using standard preservation solution

06

What researchers measure

Primary outcomes

  1. 30 days mortality and 30 days graft dysfunction

    The Primary End-Point is defined as time-to-first-event of cardiac related death, moderate or severe primary graft dysfunction of the left ventricle or primary graft dysfunction of the right ventricle (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) within 30 days.

    Time frame: 30 days

Secondary outcomes

  1. 1 year mortality and 1 year graft dysfunction

    The key secondary endpoint is defined as time-to-first-event of either any cause of death, moderate or severe PGD-LV or PGD-RV (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) or CAV ≥ 1 (according to Mehra, 2010) within 12 months.

    Time frame: 1 year

  2. 30 days and 1 year mortality and graft dysfunction

    The individual variables included in the composite primary endpoint at 30 days and 1 year analyzed as time-to-first-event.

    Time frame: 30 days and 1 year

  3. CKMB

    Creatine kinase MB (CKMB) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal

    Time frame: 3 days

  4. TnI

    Tropinin I (TnI) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal

    Time frame: 3 days

  5. ProBNP

    Pro Brain Natriuretic Protein (ProBNP) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal

    Time frame: 3 days

  6. Stay in ICU

    Length of Stay at Intensive Care Unit, reported as number of days

    Time frame: 1 year

  7. Cardiac Transplant Events

    Incidence of Major Adverse Cardiac Transplant Events

    Time frame: 1 year

  8. Postoperative use of mechanical circulatory support

    Incidence of use of postoperative mechanical circulatory support, reported as number of days

    Time frame: 1 year

  9. Postoperative duration of mechanical circulatory support

    Duration of use of postoperative mechanical circulatory support, reported as number of days

    Time frame: 1 year

  10. Overall success/failure 30 days

    Success is defined as a recipient that are transplanted and alive at 30 days without any of the complication in the primary endpoint before 30 days.

    Time frame: 30 days

  11. Overall success/failure 1 year

    Success is defined as a recipient that are transplanted and alive at 1 year without any of the complication given in key secondary endpoint before 1 year.

    Time frame: 1 year

  12. ECHO data (Left ventricular ejection fraction)

    ECHO data with Left ventricular ejection fraction in percentage within 24 hours after transplantation

    Time frame: 24 hours

  13. ECHO data (Left ventricular ejection fraction)

    ECHO data with Left ventricular ejection fraction in percentage 1 week after transplantation

    Time frame: 1 week

  14. ECHO data (Left ventricular ejection fraction)

    ECHO data with Left ventricular ejection fraction in percentage 6 months after transplantation

    Time frame: 6 months

  15. ECHO data (Left ventricular ejection fraction)

    ECHO data with Left ventricular ejection fraction in percentage 1 year after transplantation

    Time frame: 1 year

  16. ECHO data (Right ventricular ejection fraction)

    ECHO data with Right ventricular ejection fraction in percentage within 24 hours after transplantation

    Time frame: 24 hours

  17. ECHO data (Right ventricular ejection fraction)

    ECHO data with Right ventricular ejection fraction in percentage 1 week after transplantation

    Time frame: 1 week

  18. ECHO data (Right ventricular ejection fraction)

    ECHO data with Right ventricular ejection fraction in percentage 6 months after transplantation

    Time frame: 6 months

  19. ECHO data (Right ventricular ejection fraction)

    ECHO data with Right ventricular ejection fraction in percentage 1 year after transplantation

    Time frame: 1 year

  20. ECHO data (Tricuspid annular plane systolic excursion)

    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm within 24 hours after transplantation

    Time frame: 24 hours

  21. ECHO data (Tricuspid annular plane systolic excursion)

    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 week after transplantation

    Time frame: 1 week

  22. ECHO data (Tricuspid annular plane systolic excursion)

    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 6 months after transplantation

    Time frame: 6 months

  23. ECHO data (Tricuspid annular plane systolic excursion)

    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 year after transplantation

    Time frame: 1 year

Other outcomes

  1. Serious adverse device effects

    Incidence of any serious adverse device effects.

    Time frame: 1 year

  2. Adverse device effects

    Incidence of any adverse device effects

    Time frame: 1 year

  3. Device dysfunction resulting in loss of transplantable heart

    Number of transplantable hearts lost due to device dysfunction

    Time frame: 12 hours

  4. Intra operative details; duration of ECC

    Duration of ECC in minutes

    Time frame: 12 hours

  5. Intra operative details; duration of cross clamp

    Duration of cross clamp in minutes

    Time frame: 12 hours

  6. Intra operative details; duration of surgery

    Duration of surgery in minutes

    Time frame: 12 hours

  7. Intra operative details; attempts to wean off ECC

    Number of attempts to wean off ECC

    Time frame: 12 hours

  8. Intra operative details; need for inotropic support

    Need for inotropic support (inotropic score)

    Time frame: 12 hours

  9. Intra operative details; need for pulmonary vasodilator

    Need for pulmonary vasodilator

    Time frame: 12 hours

  10. Intra operative details; defibrillations

    Number of defibrillations

    Time frame: 12 hours

  11. Intra operative details; arryhythmias

    Occurence of arryhythmias

    Time frame: 12 hours

  12. Intra operative details; conduction abnormalities

    Number of conduction abnormalities

    Time frame: 12 hours

  13. Intra operative details; Left ventricular ejection fraction (LVEF)

    LVEF in percentage

    Time frame: 12 hours

  14. Intra operative details; Right ventricular ejection fraction (RVEF)

    RVEF in percentage

    Time frame: 12 hours

  15. Intra operative details; Mitral valve regurgitations

    Grade of mitral valve regurgitations

    Time frame: 12 hours

  16. Intra operative details; Tricuspid valve regurgitations

    Occurence of tricuspid vavle regurgitations

    Time frame: 12 hours

  17. Arterial blood gas lactate

    Arterial blood gas lactate at 6 hours

    Time frame: 6 hours

  18. Arterial blood gas lactate

    Arterial blood gas lactate at 24 hours

    Time frame: 24 hours

  19. Pro-BNP during follow up

    Pro-BNP at predefined time points during follow-up.

    Time frame: 1 year

07

Study locations

15 sites
08

References and documents

Publications

  • Rega F, Lebreton G, Para M, Michel S, Schramm R, Begot E, Vandendriessche K, Kamla C, Gerosa G, Berman M, Boeken U, Clark S, Ranasinghe A, Ius F, Forteza A, Pivodic A, Hennig F, Guenther S, Zuckermann A, Knosalla C, Dellgren G, Wallinder A; NIHP2019 investigators. Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial. Lancet. 2024 Aug 17;404(10453):670-682. doi: 10.1016/S0140-6736(24)01078-X. PubMed 39153817 ↗
  • Brouckaert J, Dellgren G, Wallinder A, Rega F. Non-ischaemic preservation of the donor heart in heart transplantation: protocol design and rationale for a randomised, controlled, multicentre clinical trial across eight European countries. BMJ Open. 2023 Dec 28;13(12):e073729. doi: 10.1136/bmjopen-2023-073729. PubMed 38154894 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Aug 2023, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2019
First posted
Jun 19, 2019
StartActual
Nov 25, 2020
Primary completionActual
Aug 31, 2023
CompletionEst.
Dec 31, 2028
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03991923
Lead sponsor
XVIVO Perfusion
Responsible party
Sponsor
First posted
Jun 19, 2019
Start date
Nov 25, 2020
Primary completion
Aug 31, 2023
Completion
Dec 31, 2028 (estimated)
Last update
Apr 21, 2026

Study contacts

Filip Rega, MD, PhD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion